These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 20921918)
1. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pedapati EV; Bateman ST Pediatr Crit Care Med; 2011 Mar; 12(2):e102-7. PubMed ID: 20921918 [TBL] [Abstract][Full Text] [Related]
2. Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report. Schwarz KA; Cantrell FL; Vohra RB; Clark RF Pediatr Emerg Care; 2007 Sep; 23(9):651-2. PubMed ID: 17876257 [TBL] [Abstract][Full Text] [Related]
3. Adverse effects in children after unintentional buprenorphine exposure. Geib AJ; Babu K; Ewald MB; Boyer EW Pediatrics; 2006 Oct; 118(4):1746-51. PubMed ID: 17015570 [TBL] [Abstract][Full Text] [Related]
4. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. Lavonas EJ; Banner W; Bradt P; Bucher-Bartelson B; Brown KR; Rajan P; Murrelle L; Dart RC; Green JL J Pediatr; 2013 Nov; 163(5):1377-83.e1-3. PubMed ID: 23993129 [TBL] [Abstract][Full Text] [Related]
5. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center. Toce MS; Burns MM; O'Donnell KA Clin Toxicol (Phila); 2017 Jan; 55(1):12-17. PubMed ID: 27756148 [TBL] [Abstract][Full Text] [Related]
6. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Kim HK; Smiddy M; Hoffman RS; Nelson LS Pediatrics; 2012 Dec; 130(6):e1700-3. PubMed ID: 23129079 [TBL] [Abstract][Full Text] [Related]
7. Toxicity of buprenorphine overdoses in children. Hayes BD; Klein-Schwartz W; Doyon S Pediatrics; 2008 Apr; 121(4):e782-6. PubMed ID: 18381506 [TBL] [Abstract][Full Text] [Related]
8. Buprenorphine prescribing practices and exposures reported to a poison center--Utah, 2002-2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(49):997-1001. PubMed ID: 23235296 [TBL] [Abstract][Full Text] [Related]
9. Medical outcomes associated with nonmedical use of methadone and buprenorphine. Lee S; Klein-Schwartz W; Welsh C; Doyon S J Emerg Med; 2013 Aug; 45(2):199-205. PubMed ID: 23669129 [TBL] [Abstract][Full Text] [Related]
10. Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures. Wang GS; Severtson SG; Bau GE; Dart RC; Green JL Pediatrics; 2018 Jun; 141(6):. PubMed ID: 29724879 [TBL] [Abstract][Full Text] [Related]
11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
12. Unintentional methadone and buprenorphine exposures in children: Developing prevention messages. Schwartz L; Mercurio-Zappala M; Howland MA; Hoffman RS; Su MK J Am Pharm Assoc (2003); 2017; 57(2S):S83-S86. PubMed ID: 28292505 [TBL] [Abstract][Full Text] [Related]
13. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. Mégarbane B; Buisine A; Jacobs F; Résière D; Chevillard L; Vicaut E; Baud FJ J Subst Abuse Treat; 2010 Jun; 38(4):403-7. PubMed ID: 20189341 [TBL] [Abstract][Full Text] [Related]
14. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone. Soeffing JM; Rastegar DA J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414 [TBL] [Abstract][Full Text] [Related]
15. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Tofil NM; Benner KW; Faro SJ; Winkler MK Pediatr Crit Care Med; 2006 May; 7(3):252-4. PubMed ID: 16575353 [TBL] [Abstract][Full Text] [Related]
16. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Lai Becker M; Huntington N; Woolf AD Pediatrics; 2009 Feb; 123(2):e305-11. PubMed ID: 19124581 [TBL] [Abstract][Full Text] [Related]
17. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Correia CJ; Walsh SL; Bigelow GE; Strain EC Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637 [TBL] [Abstract][Full Text] [Related]
18. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study. Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758 [TBL] [Abstract][Full Text] [Related]
19. Posttraumatic stress disorder in children and their parents following admission to the pediatric intensive care unit: a review. Nelson LP; Gold JI Pediatr Crit Care Med; 2012 May; 13(3):338-47. PubMed ID: 21499173 [TBL] [Abstract][Full Text] [Related]
20. Opioid-induced respiratory effects: new data on buprenorphine. Dahan A Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]